Search

Grifols SA

Gesloten

SectorFinanciƫn

11.285 -0.83

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

11.27

Max

11.305

Belangrijke statistieken

By Trading Economics

Inkomsten

57M

117M

Verkoop

-85M

1.9B

K/W

Sectorgemiddelde

25.977

27.91

EPS

0.19

Dividendrendement

1.28

Winstmarge

6.19

Werknemers

23,833

EBITDA

-135M

347M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+6.1% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

1.28%

4.01%

Volgende Winsten

4 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

3.1B

6.9B

Vorige openingsprijs

12.12

Vorige sluitingsprijs

11.285

Nieuwssentiment

By Acuity

50%

50%

206 / 528 Rangschikking in Finance

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

Grifols SA Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

2 apr 2025, 17:19 UTC

Acquisities, Fusies, Overnames

Grifols in 'Very Preliminary Talks' With Brookfield Over Renewed Takeover Bid -- 2nd Update

2 apr 2025, 13:02 UTC

Acquisities, Fusies, Overnames

Grifols, Brookfield Deny Takeover Talks After Report of Renewed Interest -- Update

2 apr 2025, 10:13 UTC

Acquisities, Fusies, Overnames

Grifols Board Denies Media Reports Over Talks With Brookfield for Another Takeover Bid

28 jul 2025, 10:51 UTC

Marktinformatie

U.S.-EU Tariff Deal, Earnings Could Keep Pharma Rally Going -- Market Talk

15 apr 2025, 09:55 UTC

Marktinformatie

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

2 apr 2025, 09:27 UTC

Populaire aandelen

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

Grifols SA Prognose

Koersdoel

By TipRanks

6.1% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 12Ā EURĀ  6.1%

Hoogste 12Ā EUR

Laagste 12Ā EUR

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Grifols SA - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

1 ratings

0

Buy

1

Hold

0

Sell

Technische score

By Trading Central

N/A / 8.566Steun & Weerstand

Korte Termijn

Bearish Evidence

Gemiddeld Termijn

Very Strong Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

206 / 528 Rangschikking in Financiƫn

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Grifols SA

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.
help-icon Live chat